The Rosen Law Firm, P.A. announces that it is investigating potential
civil securities claims against Osiris Therapeutics, Inc. (NASDAQ:OSIR)
resulting from allegations that the Company may have issued materially
false statements to investors about the development and progress of its
On October 21, 2013, shares fell $2.98 or by 17.01%, closing at $14.51.
This occurred after the Company revealed that the Food and Drug
Administration ("FDA") classified OSIR's wound care product, Grafix, as
a drug thereby requiring additional regulatory measures. On September
26, 2013, OSIR received an untitled letter from the FDA raising
compliance and regulatory issues with several of the Company's products.
In their press release on October 21, 2013, OSIR stated that it reached
an agreement with the FDA on September 30, 2013. Part of that agreement
includes that OSIR will have to file a Biologics License Application in
order to obtain the drug's approval from the FDA.
The Rosen Law Firm is investigating a securities cass action lawsuit on
behalf of OSIR investors. If you have any information to aid the
investigation or if you purchased or acquired OSIR stock on or before
October 21, 2013 and would like to recover your losses, please visit the
website at http://rosenlegal.com/cases-215.html
for more information. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.The
Rosen Law Firm P.A.275 Madison Avenue 34th FloorNew
York, New York 10016Tel: (212) 686-1060Toll Free:
1-866-767-3653Fax: (212) email@example.com@firstname.lastname@example.org
[ Back To NFVZone's Homepage ]